If mTOR pathways are normally down-regulated in tumor hypoxia, drug inhibitors of the mTOR pathway may not be a successful treatments for high-grade gliomas as the target may already be depressed, a conclusion supported by current clinical trials of mTOR inhibitors in glioblastoma patients [32-35]. This evidence concerns the gene MTOR and central nervous system cancer.